DALLAS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI ... Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI ...
The FDA's provisional determination of interchangeability ... Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI (ustekinumab-aekn ...
(RTTNews) - NKGen Biotech (NKGN), Friday revealed the administration of the first dose of its autologous NK cell therapy, troculeucel, to a frontotemporal dementia or FTD patient under an FDA ...
The FDA will review the applications under priority ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval, indicating strong initial market uptake. Attruby™ is the first and only near ...
(RTTNews) - Harmony Biosciences Holdings, Inc. (HRMY) Wednesday said that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the ...
Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ...
(RTTNews) - Northstrive Biosciences, a subsidiary of PMGC Holdings Inc. (ELAB), on Tuesday announced the submission of a pre-investigational New Drug or pre-IND meeting request to the FDA for EL-22.
The closing of the business combination with PowerUp Acquisition Corp. creates Nasdaq-listed biopharmaceutical company dedicated to developing breakthrough innovations in FDA approved drugs, ...
Rhythm (Nasdaq: IRTC) shares got a boost today on fourth-quarter results that came in ahead of the consensus forecast on Wall ...
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...
Jim Jones, a deputy commissioner at the U.S. Food and Drug Administration, resigned Monday following what he called the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results